ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2023

Abstract Number: 2254

The Effects of Interleukin 17 Inhibitors on Major Adverse Cardiovascular Events in Patients Naïve to Biologic Agents with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Ruoning Ni1, Jiayi Zheng2, Ruru Guo3 and Bharat Kumar4, 1University of Iowa Hospitals and Clinics, Coralville, IA, 2The Wright Center for Graduate Medical Education, Scranton, PA, 3Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 4University of Iowa Hospitals and Clinics, Iowa City, IA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2023

Keywords: Biologicals, Cardiovascular, Interleukins, Psoriatic arthritis, Stroke

Session Information

Date: Tuesday, November 14, 2023

Title: (2227–2256) Spondyloarthritis Including Psoriatic Arthritis – Treatment: SpA Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The aim of this systematic review is to determine the effects of IL-17 inhibitors on major adverse cardiovascular events (MACEs) in patients with psoriasis (PsO) or psoriatic arthritis (PsA).

Methods: A search for randomized controlled trials of patients with PsO/PsA treated with IL-17 inhibitors that reported confirmed MACEs was conducted on December 7, 2022, in Medline, Embase, and the Cochrane Library for Randomized Controlled Trials. Two reviewers screened titles and abstracts and selected papers for full-text review. Trials that included the previous use of biologic disease modifying anti-rheumatic drugs were excluded. Risk ratios were calculated by the Mantel-Haenszel random-effect method. Heterogeneity across studies was measured by χ2 test and I2 statistics. Funnel plot analysis was produced to detect potential publication bias.

Results: Of the 919 references identified, 9 RCT studies were eligible for quantitative synthesis (n=2096 patients). The use of IL-17 inhibitors was not correlated with a statistically significant change in the risk of MACEs (Risk Ratio 0.56; 95% CI 0.15 to 2.14; p= 0.40). Subgroup analysis of secukinumab or ixekizumab also did not demonstrate changes in the risk for MACEs. Additionally, there was no detectable dose-dependent effect of IL-17 inhibitors on the risk of MACEs.

Conclusion: IL-17 inhibitor use is not correlated with a change in risk for major adverse cardiovascular in patients with PsO/PsA that have not previously received biologic disease-modifying anti-rheumatic drugs.

Supporting image 1

Flow chart of included randomized controlled trials.

Supporting image 2

Relative Risks (RRs) of all major adverse cardiovascular events (MACEs) in patients with psoriasis (PsO) and/or psoriatic arthritis (PsA) treated with interleukin 17 (IL_17) inhibitors compared with placebo or disease-modifying antirheumatic drugs (DMARDs) in randomized controlled trials (RCTs) using the Mantel-Haenszel (M-H) random-effect method. P-Y, patient-year.

Supporting image 3

RRs of all MACEs in patients with PsO/PsA treated with different dosages of IL_17 inhibitors in RCTs using the M-H random-effect method. P-Y, patient-year.


Disclosures: R. Ni: None; J. Zheng: None; R. Guo: None; B. Kumar: None.

To cite this abstract in AMA style:

Ni R, Zheng J, Guo R, Kumar B. The Effects of Interleukin 17 Inhibitors on Major Adverse Cardiovascular Events in Patients Naïve to Biologic Agents with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-effects-of-interleukin-17-inhibitors-on-major-adverse-cardiovascular-events-in-patients-naive-to-biologic-agents-with-psoriasis-or-psoriatic-arthritis-a-systematic-review-and-meta-analysis-of-ran/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effects-of-interleukin-17-inhibitors-on-major-adverse-cardiovascular-events-in-patients-naive-to-biologic-agents-with-psoriasis-or-psoriatic-arthritis-a-systematic-review-and-meta-analysis-of-ran/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology